211 related articles for article (PubMed ID: 25527633)
1. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
[TBL] [Abstract][Full Text] [Related]
3. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
4. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
5. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
Jin M; Long ZW; Yang J; Lin X
Pathol Oncol Res; 2018 Jan; 24(1):45-57. PubMed ID: 28188432
[TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
7. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
8. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
9. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
Dinchuk JE; Cao C; Huang F; Reeves KA; Wang J; Myers F; Cantor GH; Zhou X; Attar RM; Gottardis M; Carboni JM
Endocrinology; 2010 Sep; 151(9):4123-32. PubMed ID: 20610571
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
12. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
13. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
14. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
19. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
20. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
